Havemeyer Place LP Makes New $1.49 Million Investment in Moderna, Inc. $MRNA

Havemeyer Place LP bought a new position in shares of Moderna, Inc. (NASDAQ:MRNA) during the fourth quarter, HoldingsChannel.com reports. The firm bought 50,387 shares of the company’s stock, valued at approximately $1,486,000.

A number of other hedge funds also recently modified their holdings of MRNA. Norges Bank acquired a new stake in shares of Moderna during the fourth quarter worth about $79,707,000. Invesco Ltd. raised its position in shares of Moderna by 15.7% during the third quarter. Invesco Ltd. now owns 8,216,163 shares of the company’s stock worth $212,223,000 after purchasing an additional 1,115,131 shares during the period. Worldquant Millennium Advisors LLC acquired a new stake in shares of Moderna during the second quarter worth about $23,192,000. Bank of America Corp DE raised its position in shares of Moderna by 84.3% during the second quarter. Bank of America Corp DE now owns 1,779,309 shares of the company’s stock worth $49,091,000 after purchasing an additional 813,974 shares during the period. Finally, Theleme Partners LLP raised its position in shares of Moderna by 8.6% during the second quarter. Theleme Partners LLP now owns 7,868,810 shares of the company’s stock worth $217,100,000 after purchasing an additional 626,420 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

Insider Buying and Selling

In other Moderna news, Director Noubar Afeyan sold 9,263 shares of the company’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $46.84, for a total value of $433,878.92. Following the completion of the transaction, the director owned 3,924 shares of the company’s stock, valued at $183,800.16. This represents a 70.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, President Stephen Hoge sold 53,336 shares of the company’s stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $48.40, for a total value of $2,581,462.40. Following the completion of the transaction, the president directly owned 1,477,997 shares of the company’s stock, valued at approximately $71,535,054.80. The trade was a 3.48% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 68,281 shares of company stock worth $3,280,293 in the last ninety days. 10.80% of the stock is owned by insiders.

Moderna Stock Performance

NASDAQ:MRNA opened at $47.44 on Monday. The stock has a fifty day moving average price of $49.83 and a 200-day moving average price of $43.31. The company has a market cap of $18.82 billion, a price-to-earnings ratio of -5.82 and a beta of 1.05. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.35 and a current ratio of 2.41. Moderna, Inc. has a fifty-two week low of $22.28 and a fifty-two week high of $59.55.

Moderna (NASDAQ:MRNA) last released its earnings results on Friday, May 1st. The company reported ($3.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.02) by ($0.38). Moderna had a negative net margin of 143.55% and a negative return on equity of 26.64%. The company had revenue of $389.00 million for the quarter, compared to the consensus estimate of $236.37 million. During the same quarter in the previous year, the company posted ($2.52) earnings per share. The business’s revenue was up 260.2% compared to the same quarter last year. As a group, equities analysts anticipate that Moderna, Inc. will post -6.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. Morgan Stanley set a $33.00 target price on Moderna in a research report on Friday, May 1st. Citigroup reiterated a “neutral” rating on shares of Moderna in a research note on Monday, February 16th. Piper Sandler lifted their target price on Moderna from $63.00 to $69.00 and gave the stock an “overweight” rating in a research note on Monday, February 23rd. Jefferies Financial Group set a $37.00 target price on Moderna and gave the stock a “hold” rating in a research note on Tuesday, March 3rd. Finally, Royal Bank Of Canada lifted their target price on Moderna from $35.00 to $38.00 and gave the stock a “sector perform” rating in a research note on Monday, May 4th. Two analysts have rated the stock with a Buy rating, eleven have given a Hold rating and five have issued a Sell rating to the company’s stock. According to MarketBeat, Moderna presently has an average rating of “Reduce” and an average target price of $35.73.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.